Sanofi SA
SAN: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€443.00 | Zmkf | Xzwsvykw |
Sanofi Earnings: Strong Dupixent Sales Offset Generic Pressures as Pipeline Makes Solid Progress
Sanofi reported second-quarter results largely as expected and consistent with our fair value estimate. We continue to view the company as undervalued, with the market not fully appreciating a growing pipeline and the very well-positioned immunology drug Dupixent, both of which also give us confidence in the firm’s wide moat.